The lowest and highest of the models that produced a value. This is the spread of the methods, not a price target.
Price target range & 52-week position
Bear¥114.92Fair value¥696.71Bull¥1,581.17
FairClose
52-week traded range
52W low ¥556.0052W high ¥937.00
The 52-week range is measured from the stored price history, not estimated.
Valuation summary
Trading above the consensus fair value
EnBio Holdings,Inc closed at ¥812.00, 16.5% above the consensus fair value of ¥696.71 drawn from 9 valuation models.
Financial DNA score 48/100 — Average. P/E of 24.8x against the 20x sector multiple the P/E model uses.
Quantitative summary only — not investment advice.
All valuation models
DCF Valuation
¥275.47
-66.1%
Σ[CF×(1+g)^n/(1.10)^n] + TV/(1.10)^10
g=8%, r=10%, tg=3%, n=10yr
Graham Number
¥917.73
+13.0%
√(22.5 × EPS × BVPS)
EPS=32.73, BVPS=1143.66
P/E Fair Value
¥654.60
-19.4%
EPS × 20x (sector P/E)
EPS=32.73, Sector P/E=20x
Peter Lynch (PEG)
¥661.80
-18.5%
EPS × Growth% (PEG = 1 is fair)
EPS=32.73, g=20.2%
EV/EBITDA
¥1,581.17
+94.7%
(EBITDA × 10x − Net Debt) ÷ Shares
EBITDA=2.15B
Dividend Discount (DDM)
¥114.92
-85.8%
D1 ÷ (r − g) where D1 = D0×(1+g)
D0=9.01, r=10%, g=2%
Book Value (P/B)
¥331.66
-59.2%
BVPS × (ROE−g)÷(r−g) [Justified P/B — RIM-based]
BVPS=1143.66, ROE=2.9%, g=3%, r=10%
Reverse DCF
¥812.00
+0.0%
Solve for g: Price = Σ[EPS×(1+g)^n/(1.10)^n] + TV
Implied: 10.1% | Historical: -20.2%
Margin of Safety
¥461.95
-43.1%
Avg(DCF, Graham, P/E) × 75% (25% safety buffer)
Avg fair value=615.93, MoS=25%
Computed on September 12, 2026 from the most recent annual report on file and that day's closing price. Where a company has seen its earnings move sharply since its last annual report, this figure will lag the market.
Educational data only. Not a recommendation to buy, sell or hold any security.